UNSPSC 51372112: Codeine hydrobromide

This classification denotes an opiate with the molecular formula C18H21NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HOK0TIN61, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-, hydrobromide but more generally known as codeine hydrobromide, which bears US NIH Compound Identifier 5464192. European Medicines Agency schedules Codeine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13426MIG.

Most nations, for tariff and trade purposes, schedule codeine hydrobromide under HS 29391100. As of Q4 2014, CODEINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.BR.

UNSPSC 51372112 Codeine hydrobromide is a Commodity code that nominally covers pharmaceutical products in the opioid family, but state and local procurement activity under this code shows little alignment with the code's intended scope. The single recent opportunity posted under this code — Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems — does not procure codeine hydrobromide itself. Naloxone is an opioid antagonist used to reverse overdose, and drug deactivation systems are disposal or neutralization equipment, neither of which falls within the codeine hydrobromide product line. State and local buyers do not appear to be soliciting pharmaceutical opioid inventory under this specific code at present.

Seminole County's July 2026 IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a fixed-fee basis with a two-year initial term and one-year renewal option. The procurement required electronic bid submission, unit pricing, drug-free workplace certification, E-Verify compliance, and standard commercial insurance. The code's scarcity of recent activity and the mismatch between its nominal pharmaceutical scope and the harm-reduction equipment actually being procured suggest that this UNSPSC category is either misapplied in the source data or sees minimal state and local demand for codeine hydrobromide products specifically.